Erasca Stock Quote ERAS - Stock Price, News, Charts, Message Board, Trades

Real-time discussions and trading ideas: Trade with confidence with our powerful platform.

Premium

Current Price

2.585

Bid

2.58

Ask

2.59

Volume

215,107

2.54 Day's Range 2.63

1.51 52 Week Range 3.45

Market Cap

730.274M

Previous Close

2.595

Open

2.59

Last Trade

2.5794

Last Trade Time

11:34:05

Financial Volume

$ 555,132

VWAP

2.5807

Average Volume (3m)

2,202,957

Shares Outstanding

282,504,318

Dividend Yield

PE Ratio

-5.81

Earnings Per Share (EPS)

-0.44

Revenue

Net Profit

-125.04M

Erasca Inc is a clinical-stage precision oncology company singularly focused on discovering, developing, and commercializing therapies for patients with RAS/MAPK pathway-driven cancers. The company's pipeline includes two clinical-stage programs (ERK and SHP2 inhibitors), two preclinical-stage progr... Erasca Inc is a clinical-stage precision oncology company singularly focused on discovering, developing, and commercializing therapies for patients with RAS/MAPK pathway-driven cancers. The company's pipeline includes two clinical-stage programs (ERK and SHP2 inhibitors), two preclinical-stage programs (CNS-penetrant KRAS G12C and EGFR inhibitors), and seven discovery-stage programs targeting other key oncogenic drivers. Show more

Sector

Pharmaceutical Preparations

Industry

Pharmaceutical Preparations

Website

www.erasca.com

Headquarters

Wilmington, Delaware, USA

Founded

Erasca Inc is listed in the Pharmaceutical Preparations sector of the NASDAQ with ticker ERAS. The last closing price for Erasca was $2.60. Over the last year, Erasca shares have traded in a share price range of $ 1.51 to $ 3.45.

Erasca currently has 282,504,318 shares outstanding. The market capitalization of Erasca is $733.10 million. Erasca has a price to earnings ratio (PE ratio) of -5.81.

FeaturedCannabix Technologies and Omega Laboratories Inc. Advance Marijuana Breathalyzer Technology - Dr. Bruce Goldberger to Present at Society of Forensic Toxicologists Conference

FeaturedIntegrated Ventures, Inc Announces Strategic Partnership For GLP-1 (Semaglutide) Procurement Through MedWell USA, LLC.

Period	Change	Change %	Open	High	Low	Avg. Daily Vol	VWAP
1	-0.285	-9.93031358885	2.87	3.03	2.54	5374027	2.87129286	CS
4	-0.305	-10.553633218	2.89	3.1475	2.54	2818635	2.8968245	CS
12	0.155	6.37860082305	2.43	3.45	2.1	2202957	2.86404018	CS
26	0.375	16.9683257919	2.21	3.45	1.74	2010420	2.57729249	CS
52	0.345	15.4017857143	2.24	3.45	1.51	1492475	2.39742882	CS
156	-17.225	-86.9510348309	19.81	22.94	1.51	951137	4.42230229	CS
260	-13.315	-83.7421383648	15.9	24.47	1.51	924317	4.94526609	CS

Most Active
% Gainers
% Losers

Symbol	Price	Vol.
SEELSeelos Therapeutics Inc	$ 0.3984 (109.68%)	269.25M
MSSMaison Solutions Inc	$ 1.41 (97.20%)	74.94M
BNZIBanzai International Inc	$ 8.08 (92.38%)	41.14M
XHGXChange TED Inc	$ 1.1101 (79.19%)	15.91M
GBNYGenerations Bancorp NY Inc	$ 15.75 (43.18%)	285.11k
BIVIBioVie Inc	$ 1.2755 (-54.45%)	1.52M
GHSIGuardion Health Sciences Inc	$ 6.60 (-37.26%)	266.15k
XPONExpion360 Inc	$ 0.086 (-26.50%)	27.93M
FCUVFocus Universal Inc	$ 0.2497 (-24.33%)	1.34M
FIACUFocus Impact Acquisition Corporation	$ 9.10 (-21.21%)	99
SEELSeelos Therapeutics Inc	$ 0.3984 (109.68%)	269.25M
NVDANVIDIA Corporation	$ 117.3409 (0.93%)	89.47M
MLGOMicroAlgo Inc	$ 0.2147 (8.22%)	75.5M
MSSMaison Solutions Inc	$ 1.41 (97.20%)	74.94M
TRNRInteractive Strength Inc	$ 0.2699 (14.22%)	72.42M